Number To Know…28
Executive Summary
Brain tumor patients treated with a combination of tumor treatment fields (TTFields) therapy, delivered by NovoCure's Optune device, and chemotherapy have shown an increased median overall survival rate of 28%, according to data from a late-phase pivotal study.